What Happened?
, -based Kymera Therapeutics Appointed Mark McClanahan as Chief Financial Officer (CFO)
Date of management change: September 06, 2022
, -based Kymera Therapeutics Appointed Mark McClanahan as Chief Financial Officer (CFO)
Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.
Mark McClanahan is Chief Financial Officer (CFO) at Kymera Therapeutics. Previously, Mark held various senior HR leadership roles in the industry.
News
Other IT executives who recently changed jobs as well: Kinkle Jill, Blevins Bonnie, Magliocca Evan, Braithwaite Linda, Haverty Carol, Suttle Andrea, Fadina Aina, Walz Cynthia, Carroll Derek, Peters Bret, Rubio Rafael
You can find the full directory of IT executives here.
How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.